biotechnology and ipr issuesris.org.in/images/ris_images/pdf/pravin_anand.pdfworld intellectual...
Post on 07-Jul-2020
4 Views
Preview:
TRANSCRIPT
Pravin Anand
April 7th, 2004
Biotechnology and IPR issues
Some issues
• Why IP• What IP• The essentials• Skills• Commercialisation
•Assignments and licensing
Recent Changes
Three themes:1.In the Patent
environment2.Protection with
reference to the New Act and Traditional Knowledge
3.Enforcement
A. Environment
Knowledge of Patents reachingrural inventors
Inventors expressing Dissatisfaction with the system
1. Inventors Awareness
Letter from an Inventor
Heaviest Kite in the World
“IP is critical in this new global regime”
2.Patent Office and Government
Website of The Indian Patent Office
World Intellectual Property Day26th April 2003
B. Protection (recent Past)
– Inventions required tangible end product
– Weak Protection for Pharmaceutical, Food and Chemical Patents
– Biotechnology –protection was non existent
– Computer Software was not protected
– Enforcement climate was weak
– Non members of major International Treaties on Patents
Changes
1.Members of Paris, PCT, Budapest conventions
2.TRIPS – 1995 obligations met 4 years late by introducing EMR’s in 1999
3. TRIPS 2000 obligations met in may 2003 by Patent (Second Amendment)Act 2002 coming into force on 20.5.03
4. Interactive sessions (15 to 20) are being organised by the Government to try and make it on time
Changes
1 Request for examination can be filed with the application or deferred upto 4 years2 Disclosures of foreign applications has been made too burdensome with some time criticality3 Parallel importation4 Bolar provisions
Patent Amendments of 2002 –Pharmaceuticals , food etc
• Term of Pharma, Food, Agro-Chem Patents increased from 7 to 20 years
• License of right – repealed• Products can be patented from
2005 and EMR (Exclusive Marketing Right) in meanwhile
• Reversal of burden of proof
EMR cases
-8 EMR cases eg SKB; Hoffman LaRoche, Novartis, UP, Ranbaxy
Biotechnology
• Processes for producing living matter now allowed– Law interpreted in Dimminaco
AG– Amendment clarified
• Micro-organisms or living substances themselves still excluded
• 3rd Amendment would protect them – IMTECH established as an IDA in Chandigarh
Dimminaco ‘s case
Process for Manufacture of a live vaccine forprotecting poultry from infectious Bursitis
Traditional Knowledge (TK)
• What is TK?–At least one generation old
if passed on from generation to generation
–Knowledge wide – herbal medicines to folklore
–Communities have preserved TK and it is distinctive of them
Many legislations involved
• Patents Act:– Excludes TK as not being an
invention (S 3)– If Biological material mentioned
in application then apart from deposit requirements – source and geographical origin necessary – does not say country(S 10)
TK – hottest issue
• Biological Diversity Act 2002• No person can apply for an IPR based on a
biological resource from India without Prior consent of National Biodiversity Authority
• Can be obtained any time before sealing• NBA shall decide within 90 days• Benefit Sharing and royalty from commercial
exploitation of such IP rights
C. Enforcement
• The Litigation environment changing
• CPC amendments – a contested suit can be disposed of within 2 years now
• Shift from the need for an Injunction to damages
Franz Xaver Huemer’s case
• Injunction refused only because the Plaintiff had not used the patent in India
Thomas Brandt case (Tangibility)
• Process for opacification of a gaseous medium
• Need not be a tangible end product HC remanded –yet PO refused
• New Act makes position clear
Wet Grinder
Schneider vs Telemechanique
Injunction against JointVenture when permission toMake generation 2 productsDeclined
No Acquiescence
Philips VCD Cases
Philips VCD Compression Technology – Injunctions in Two Suits: Anton Pillers executedLicenses of US$ 200,000 in One month
Conclusion
1.From the days of the EMR amendments legislative working is more transparent and pro patents2. From the days of Thomas Brandt the Patent office has gone far3. From the days of Franz Xaver Huemerthe courts have been far stronger in favourof Patents4. Data exclusivity issues
top related